Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Nabpaclitaxel in Advanced Solid Tumors and Recurrent Endometrial or Ovarian Cancer
NCT02117817Phase 1Withdrawn
- Sponsor
- Rutgers University
- Start
- Feb 2015
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of buparlisib in solid tumor, endometrial cancer (EC) and ovarian cancer, sponsored by Rutgers University. Primary endpoints: Incidence of adverse events graded according to CTCAE v4.0 at 2 years and Maximum Tolerated Dose and Dose-Limiting Toxicity. Planned start Feb 2015; status: withdrawn.
02
Drugs
buparlisib
03
Conditions
solid tumorendometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT02117817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117817.